
    
      The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting
      efficacy of a single agent such as premetrexed a reasonable objective since these
      malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to
      antineoplastic agents.
    
  